Fulvestrant
Fulvestrant je organsko jedinjenje, koje sadrži 32 atoma ugljenika i ima molekulsku masu od 606,771 Da.[1][2][3][4][5]
 | |
| Klinički podaci | |
|---|---|
| Drugs.com | Monografija |
| Način primene | Intramaskularno |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 40 dana |
| Izlučivanje | Fekalno |
| Identifikatori | |
| CAS broj | 129453-61-8  |
| ATC kod | L02BA03 (WHO) |
| PubChem | CID 104741 |
| IUPHAR/BPS | 1015 |
| DrugBank | DB00947 |
| ChemSpider | 94553 |
| ChEBI | CHEBI:31638 |
| ChEMBL | CHEMBL1358 |
| Hemijski podaci | |
| Formula | C32H47F5O3S |
| Molarna masa | 606,771 |
| |
| |
Osobine уреди
| Osobina | Vrednost |
|---|---|
| Broj akceptora vodonika | 3 |
| Broj donora vodonika | 2 |
| Broj rotacionih veza | 15 |
| Particioni koeficijent[6] (ALogP) | 8,4 |
| Rastvorljivost[7] (logS, log(mol/L)) | -11,3 |
| Polarna površina[8] (PSA, Å2) | 76,7 |
Reference уреди
- ^ Kansra S, Yamagata S, Sneade L, Foster L, Ben-Jonathan N: Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36. PMID 15950373
- ^ Kabos P, Borges VF: Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer. Expert Opin Pharmacother. 2010 Apr;11(5):807-16. PMID 20151846
- ^ Bross PF, Cohen MH, Williams GA, Pazdur R: FDA drug approval summaries: fulvestrant. Oncologist. 2002;7(6):477-80. PMID 12490735
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709
. PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
- ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
- ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
- ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.
Literatura уреди
- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze уреди
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
Категорија:Хемотерапијски агенси